On November 8, the CDE official website showed that the application for the marketing of biosimilar biosimilars of Biotetozumab was accepted by the State Food and Drug Administration. The research and development of domestic monoclonal antibody drugs has been gradually applied for the market from the clinical stage, and COP bottles, as an important packaging form of such drugs, will also usher in growth under the influence of the industry.
Tocilizumab injection (tocilizumab) was developed by Chugai Pharmaceutical (Roche). It is a humanized anti-human interleukin 6 receptor (IL-6R) monoclonal antibody preparation expressed in mammalian cells (CHO). Named: Actemra (Actemra). Tocilizumab can block the binding of interleukin 6 to the soluble and membrane-bound interleukin 6 receptor and inhibit the signal transduction of interleukin 6, thereby reducing pathological inflammation.
At present, there are two indications approved for the study of Tocillin antigen in my country, namely: adult rheumatoid arthritis and systemic juvenile idiopathic arthritis. As tocilizumab injection's original molecular protection patent has expired, domestic and foreign pharmaceutical companies have devoted themselves to the research and development of their biosimilar drugs. CDE official website data shows that as of November 10, the number of new drugs declared for marketing in 2021 has reached 104, which shows that Chinese pharmaceutical companies are making rapid progress in the research and development of monoclonal antibody drugs, and the industry is about to usher in a period of stable development. The development of the industry will inevitably drive the prosperity of its upstream and downstream industrial chains, such as COP vials and other pharmaceutical packaging.
COP vial is a plastic bottle made of cycloolefin polymer added with organic solvent and processed by injection stretch blowing process. It has the characteristics of strong temperature resistance, low protein adsorption, low birefringence, high rigidity, and high transparency. It is a common packaging for monoclonal antibodies and other biological drugs. With the rapid development of the industry, this kind of packaging will also usher in an increase in market demand.
Note: Part of the content is derived from Medicine Rubik's Cube Info
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
MAKE AN ENQUIRY
